VolitionRx (VNRX) announces results from a clinical study demonstrating the high accuracy of its Nu.Q Vet Feline assay in detecting lymphoma in cats, the most common cancer in the species. At 100% specificity, i.e. no false positives, the assay detected over 80% of feline lymphomas. This breakthrough marks the development of what we expect to be the world’s first simple, affordable blood-based liquid biopsy test for feline cancer, a significant unmet need in veterinary medicine.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNRX:
- VolitionRX Announces CEO Departure Amid Cost Realignment
- VolitionRx announces new paper on Capture-Seq, achieves 180-fold enrichment
- VolitionRX Gains Momentum with Strategic Advancements in Sepsis and Cancer Diagnostics
- VolitionRx downgraded to Hold from Buy at Maxim
- VolitionRx price target lowered to $1.50 from $2.50 at H.C. Wainwright